These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cerebrospinal fluid markers of neuronal and glial cell damage in patients with autoimmune neurologic syndromes with and without underlying malignancies. Constantinescu R; Krýsl D; Andrén K; Asztély F; Bergquist F; Zetterberg H; Andreasson U; Axelsson M; Menachem EB; Jons D; Mahamud U; Malmeström C; Rosengren L; Blennow K J Neuroimmunol; 2017 May; 306():25-30. PubMed ID: 28385184 [TBL] [Abstract][Full Text] [Related]
4. Serum and cerebrospinal fluid brain damage markers neurofilament light and glial fibrillary acidic protein correlate with tick-borne encephalitis disease severity-a multicentre study on Lithuanian and Swedish patients. Veje M; Griška V; Pakalnienė J; Mickienė A; Bremell D; Zetterberg H; Blennow K; Lindquist L; Studahl M Eur J Neurol; 2023 Oct; 30(10):3182-3189. PubMed ID: 37431060 [TBL] [Abstract][Full Text] [Related]
5. Glial and neuroaxonal biomarkers in a multiple sclerosis (MS) cohort. Kalatha T; Hatzifilippou E; Arnaoutoglou M; Balogiannis S; Koutsouraki E Hell J Nucl Med; 2019; 22 Suppl 2():113-121. PubMed ID: 31802051 [TBL] [Abstract][Full Text] [Related]
6. CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease. van Eijk JJ; van Everbroeck B; Abdo WF; Kremer BP; Verbeek MM J Alzheimers Dis; 2010; 21(2):569-76. PubMed ID: 20555148 [TBL] [Abstract][Full Text] [Related]
7. An exploratory study of the damage markers NfL, GFAP, and t-Tau, in cerebrospinal fluid and other findings from a patient cohort enriched for suspected autoimmune psychiatric disease. Syk M; Tornvind E; Gallwitz M; Fällmar D; Amandusson Å; Rothkegel H; Danfors T; Thulin M; Rasmusson AJ; Cervenka S; Pollak TA; Endres D; van Elst LT; Bodén R; Nilsson BM; Nordmark G; Burman J; Cunningham JL Transl Psychiatry; 2024 Jul; 14(1):304. PubMed ID: 39048548 [TBL] [Abstract][Full Text] [Related]
8. Glial and neuronal markers in cerebrospinal fluid in different types of multiple sclerosis. Mañé-Martínez MA; Olsson B; Bau L; Matas E; Cobo-Calvo Á; Andreasson U; Blennow K; Romero-Pinel L; Martínez-Yélamos S; Zetterberg H J Neuroimmunol; 2016 Oct; 299():112-117. PubMed ID: 27725108 [TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid biomarkers in patients with neurological symptoms but without neurological diseases. Constantinescu R; Mahamud U; Constantinescu C; Eriksson B; Novakova L; Olsson B; Rosengren L; Blennow K; Axelsson M Acta Neurol Scand; 2019 Sep; 140(3):177-183. PubMed ID: 31087810 [TBL] [Abstract][Full Text] [Related]
10. Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis. Mariotto S; Gajofatto A; Zuliani L; Zoccarato M; Gastaldi M; Franciotta D; Cantalupo G; Piardi F; Polo A; Alberti D; Sartori S; Zanusso G; Agrò L; Demurtas R; Sechi G; Sechi E; Monaco S; Ferrari S J Neurol; 2019 Jul; 266(7):1643-1648. PubMed ID: 30944980 [TBL] [Abstract][Full Text] [Related]
11. Biomarkers in the cerebrospinal fluid and neurodegeneration in Langerhans cell histiocytosis. Gavhed D; Akefeldt SO; Osterlundh G; Laurencikas E; Hjorth L; Blennow K; Rosengren L; Henter JI Pediatr Blood Cancer; 2009 Dec; 53(7):1264-70. PubMed ID: 19688833 [TBL] [Abstract][Full Text] [Related]
12. Evaluating the utility of serum NfL, GFAP, UCHL1 and tTAU as estimates of CSF levels and diagnostic instrument in neuroinflammation and multiple sclerosis. Koerbel K; Maiworm M; Schaller-Paule M; Schäfer JH; Jakob J; Friedauer L; Steffen F; Bittner S; Foerch C; Yalachkov Y Mult Scler Relat Disord; 2024 Jul; 87():105644. PubMed ID: 38701697 [TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid viral load and biomarkers of neuronal and glial cells in Ramsay Hunt syndrome. Lindström J; Grahn A; Zetterberg H; Studahl M Eur J Neurosci; 2016 Dec; 44(11):2944-2949. PubMed ID: 27643680 [TBL] [Abstract][Full Text] [Related]
14. Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Holmberg B; Rosengren L; Karlsson JE; Johnels B Mov Disord; 1998 Jan; 13(1):70-7. PubMed ID: 9452329 [TBL] [Abstract][Full Text] [Related]
15. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy. Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij HB; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326 [TBL] [Abstract][Full Text] [Related]
16. Cognitive impairment without altered levels of cerebrospinal fluid biomarkers in patients with encephalitis caused by varicella-zoster virus: a pilot study. Eckerström M; Nilsson S; Zetterberg H; Blennow K; Grahn A Sci Rep; 2020 Dec; 10(1):22400. PubMed ID: 33372192 [TBL] [Abstract][Full Text] [Related]
17. Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: A pilot study. Axelsson M; Sjögren M; Andersen O; Blennow K; Zetterberg H; Lycke J Acta Neurol Scand; 2018 Aug; 138(2):143-150. PubMed ID: 29624650 [TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid neurofilament and glial fibrillary acidic protein in patients with cerebral vasculitis. Nylén K; Karlsson JE; Blomstrand C; Tarkowski A; Trysberg E; Rosengren LE J Neurosci Res; 2002 Mar; 67(6):844-51. PubMed ID: 11891800 [TBL] [Abstract][Full Text] [Related]
20. Astrocytic damage in glial fibrillary acidic protein astrocytopathy during initial attack. Yang X; Huang Q; Yang H; Liu S; Chen B; Liu T; Yang J; Yao H; Lin S; Chen X; Zhuang H; Long Y; Gao C Mult Scler Relat Disord; 2019 Apr; 29():94-99. PubMed ID: 30690341 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]